Etanercept Market Scope
Etanercept is a tumor necrosis factor antagonist that is used for the treatment of adult and juvenile from rheumatoid arthritis, it is also known as biopharmaceutical which is also used to treat autoimmune disorders. This biopharmaceutical is the United States FDA approved to treat psoriatic arthritis, juvenile idiopathic arthritis, rheumatoid arthritis, ankylosing spondylitis, and plaque psoriasis and many more diseases. Hence, rising accidents and obesity is growing in the industry.
The market study is being classified by Type (Enbrel and Benepali), by Application (Rheumatoid arthritis, Psoriatic arthritis, Ankylosing spondylitis, Juvenile idiopathic arthritis (JIA) and Others) and major geographies with country level break-up.
Research Analyst at AMA predicts that Global Players will contribute to the maximum growth of Global Etanercept market throughout the predicted period.
Amgen (United States), Pfizer (United States), Takeda (Japan), Sanofi (France), GlaxoSmithKline (United Kingdom), Sandoz (Germany), Celltrion (South Korea), Dexa Medica (Indonesia), Bionovis (Brazil) and Momenta Pharmaceuticals (United States) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are HanAll Biopharma (South Korea), MedImmune (United States) and Tsumura (Japan).
AdvanceMarketAnalytics has segmented the market of Global Etanercept market by Type, Application and Region.
On the basis of geography, the market of Etanercept has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).
In the United States, Sandoz submitted a biologics license application (BLA) for the proposed etanercept product "GP2015" in July 2016. Upon acceptance of the first application process, the U.S. FDA reviewed data from European clinical trials and bio-analytical investigations, demonstrating the biosimilarity of GP2015 to the US-licensed Enbrel
- Increasing Prevalence of Rising Diseases such as Obesity and Accidents
- Rising Awareness about the Diseases such as Arthritis is also Driving the Market
- Growing Healthcare Expenditure and Government Support is Boosting the Industry
- Growing Government Regulation Associated with Saftey and Efficiency of Etanercept can Hamper the market
- Issue Related Towards the Side Effects of this Etanercept such as Lower Ability of Immune System, Heart failure and Many More
Key Target AudienceEtanercept Manufacture, Etanercept Distributors, Potential Investors, Pharmaceuticals and Others
Customization available in this Study:The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase